Business Description
Supriya Lifescience Ltd
ISIN : INE07RO01027
Total Employee Number:
1,071Compare
Compare
Traded in other countries / regions
543434.India IPO Date
2021-12-28Description
Supriya Lifescience Ltd is a life sciences company that develops and manufactures niche Active Pharmaceutical Ingredients (APIs), formulations, and CMO/CDMO solutions. It has a diversified portfolio across various therapeutic segments, including anaesthetic, analgesic, antihistamine, vitamins, anti-asthmatic, anti-allergic, antihypertensive, and others. Additionally, the company provides CDMO services, offers finished dosage formulations such as Sevoflurane USP liquid for inhalation, Semaglutide injection, Iohexol injection, Tramadol tablet IR, etc., and has various products in its research and development pipeline. Geographically, the company derives the majority of its revenue from Europe, and the rest comes from its business in Asia, North America, Latin America, and other markets.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.5 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 147.86 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 28.59 | |||||
Beneish M-Score | -1.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.2 | |||||
3-Year EBITDA Growth Rate | 30.5 | |||||
3-Year EPS without NRI Growth Rate | 31.2 | |||||
3-Year Book Growth Rate | 19.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.51 | |||||
9-Day RSI | 64.63 | |||||
14-Day RSI | 56.59 | |||||
3-1 Month Momentum % | -6.77 | |||||
6-1 Month Momentum % | 43.33 | |||||
12-1 Month Momentum % | 35.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.4 | |||||
Quick Ratio | 3.08 | |||||
Cash Ratio | 0.65 | |||||
Days Inventory | 183.72 | |||||
Days Sales Outstanding | 70.96 | |||||
Days Payable | 114.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.12 | |||||
Dividend Payout Ratio | 0.04 | |||||
3-Year Dividend Growth Rate | 18.6 | |||||
Forward Dividend Yield % | 0.12 | |||||
5-Year Yield-on-Cost % | 0.12 | |||||
Shareholder Yield % | 0.12 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.07 | |||||
Operating Margin % | 29.67 | |||||
Net Margin % | 22.74 | |||||
EBITDA Margin % | 34.48 | |||||
FCF Margin % | 3.84 | |||||
OCF Margin % | 21.29 | |||||
ROE % | 18.16 | |||||
ROA % | 16.18 | |||||
ROIC % | 18.25 | |||||
3-Year ROIIC % | 19.42 | |||||
ROC (Joel Greenblatt) % | 28.08 | |||||
ROCE % | 23.91 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 34.69 | |||||
Forward PE Ratio | 27.28 | |||||
PE Ratio without NRI | 34.63 | |||||
Price-to-Owner-Earnings | 49.92 | |||||
PS Ratio | 7.89 | |||||
PB Ratio | 5.75 | |||||
Price-to-Tangible-Book | 5.75 | |||||
Price-to-Free-Cash-Flow | 205.23 | |||||
Price-to-Operating-Cash-Flow | 37.05 | |||||
EV-to-EBIT | 25.23 | |||||
EV-to-EBITDA | 22.64 | |||||
EV-to-Revenue | 7.8 | |||||
EV-to-FCF | 203.06 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Projected-FCF | 6.56 | |||||
Price-to-Graham-Number | 2.9 | |||||
| Price-to-Net-Current-Asset-Value | 18.45 | |||||
Earnings Yield (Greenblatt) % | 3.96 | |||||
FCF Yield % | 0.49 | |||||
Forward Rate of Return (Yacktman) % | -5.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Supriya Lifescience Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 8,725.48 | ||
| EPS (TTM) (₹) | 24.65 | ||
| Beta | 1.2387 | ||
| 3-Year Sharpe Ratio | 0.81 | ||
| 3-Year Sortino Ratio | 1.78 | ||
| Volatility % | 55.07 | ||
| 14-Day RSI | 56.59 | ||
| 14-Day ATR (₹) | 30.520645 | ||
| 20-Day SMA (₹) | 814.565 | ||
| 12-1 Month Momentum % | 35.38 | ||
| 52-Week Range (₹) | 545.65 - 1085.5 | ||
| Shares Outstanding (Mil) | 80.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Supriya Lifescience Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Supriya Lifescience Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-10 11:00 | In 157 days | ||
| Third quarter earnings results for 2027 | 2027-02-10 | In 156 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-13 11:00 | In 68 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 67 days | ||
| General meeting for 2026 | 2026-09-24 15:00 | In 18 days | ||
| INR 1.000000 Cash Dividend | 2026-09-04 | 842.60 (-0.88%) | ||
| Annual report for 2026 | 2026-09-01 | 799.40 (-0.70%) | ||
| First quarter earnings conference call for 2027 | 2026-08-14 11:00 | 813.25 (-2.14%) | ||
| First quarter earnings results for 2027 | 2026-08-14 | 813.25 (-2.14%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-28 11:00 | 807.25 (+2.44%) |
Show
Entries
Supriya Lifescience Ltd Frequently Asked Questions
What is Supriya Lifescience Ltd(BOM:543434)'s stock price today?
The current price of BOM:543434 is ₹855.20. The 52 week high of BOM:543434 is ₹1085.50 and 52 week low is ₹545.65.
When is next earnings date of Supriya Lifescience Ltd(BOM:543434)?
The next earnings date of Supriya Lifescience Ltd(BOM:543434) is 2026-11-13 Est..
Does Supriya Lifescience Ltd(BOM:543434) pay dividends? If so, how much?
The Dividend Yield %  of Supriya Lifescience Ltd(BOM:543434) is 0.12% (As of Today), Highest Dividend Payout Ratio of Supriya Lifescience Ltd(BOM:543434) was 0.05. The lowest was 0.04. And the median was 0.04. The  Forward Dividend Yield % of Supriya Lifescience Ltd(BOM:543434) is 0.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Supriya Lifescience Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers